SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Surrozen, Inc./DE

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$23.84+0.40 (+1.71%)

Close on Oct 19, 2026

Market cap: $551.80M
P/E (TTM): –
Dividend yield: –

Dividends

Surrozen has not reported a dividend

No dividend per share appears in Surrozen's annual filings since fiscal 2019.

Where these numbers come from

Parsed from the XBRL in Surrozen's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on Apr 10, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SRZN.

Revenue growth-8.8% · median -19.1%

Operating margin-385.3% · median -357.5%

Net margin-2885.3% · median -356.9%

Company	Revenue	Growth
SGMOQ	$34.56M	-45.8%
VYGR	$34.46M	-19.1%
ALEC	$13.86M	-82.9%
LCTX	$13.08M	+19.9%
SRZN	$11.51M	-8.8%
RLAY	$10.35M	+23.9%

Company

Next earnings (est.): Nov 6, 2026, after close
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 44
Held by institutions: 91.3%
Auditor: Ernst & Young LLP
SEC CIK: 1824893

Advertisement
300 × 250